Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
Open Access
- 1 February 2012
- journal article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 19 (1), L1-L4
- https://doi.org/10.1530/ERC-11-0287
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning MeetingJournal of Clinical Oncology, 2011
- First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomasCancer, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanismsEndocrine-Related Cancer, 2008
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine TumorsClinical Cancer Research, 2007
- Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growthActa Oncologica, 2007
- Measuring the Impact of Chemotherapy on Fertility in Women With Breast CancerJournal of Clinical Oncology, 2006
- Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine TumorsJournal of Clinical Oncology, 2006
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBritish Journal of Cancer, 2003